Tirzepatide
Also known as: Zepbound, Mounjaro
Browse our Tirzepatide articles and comparisons. Choose a comparison or related article below for the evidence behind each topic.
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Eli Lilly |
| Mechanism | Dual agonist — GLP-1 + GIP receptors |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~21–23% at 72 weeks (SURMOUNT program) |
| Status | FDA-approved (Zepbound for weight loss, Mounjaro for type 2 diabetes) |
Tirzepatide compared
Comparisons involving Tirzepatide, with the limits of comparing separate trials.
Retatrutide vs Mounjaro vs Ozempic
Mounjaro and Ozempic are diabetes brands; Zepbound and Wegovy have weight-management indications. Compare their evidence with investigational retatrutide.
Updated September 8, 2026
Retatrutide vs Zepbound: What's the Difference?
Zepbound is an approved tirzepatide treatment. Retatrutide remains investigational; separate trial results do not prove a treatment advantage.
Updated September 8, 2026
Retatrutide vs Tirzepatide (Zepbound): Triple Agonist vs Dual Agonist
How retatrutide and tirzepatide differ in receptor activity, trial evidence, safety, and approval status. Direct TRIUMPH-5 results are pending.
Updated September 8, 2026
CagriSema vs Tirzepatide (Zepbound): REDEFINE 4 Head-to-Head Results
REDEFINE 4 reported 23.0% versus 25.5% weight loss under the efficacy estimand and did not meet its non-inferiority endpoint.
Updated September 8, 2026
Cagrilintide and Tirzepatide: Stacking Amylin With a Dual Agonist
Evidence for this specific combination is preclinical. CagriSema and eloralintide trials cannot establish a cagrilintide–tirzepatide dosing plan.
Updated September 8, 2026
Mazdutide vs Tirzepatide: GLP-1/Glucagon vs GLP-1/GIP Compared
Different dual-agonist mechanisms, trial populations and approvals. Separate GLORY and SURMOUNT results do not establish a head-to-head winner.
Updated September 8, 2026
Orforglipron vs Tirzepatide (Zepbound): Oral Pill vs Weekly Injection
Daily Foundayo and weekly tirzepatide have different labeled uses. Separate trials do not prove that one is twice as effective.
Updated September 8, 2026
Orforglipron vs Zepbound (Tirzepatide): Daily Pill vs Weekly Injection
Foundayo and Zepbound are approved weight-management options. Compare current offers, coverage, trial results and possible regain after switching.
Updated September 8, 2026
Survodutide vs Tirzepatide (Zepbound): Glucagon vs GIP as the Second Target
Compare Phase 3 results without mixing estimands or mistaking MASH improvement for resolution.
Updated September 8, 2026
Zepbound vs Wegovy: Which One Actually Works Better in 2026?
Zepbound produced -20.2% vs Wegovy's -13.7% weight loss in the SURMOUNT-5 head-to-head trial. Full comparison of cost, side effects, and CV data.
Updated September 8, 2026
Tirzepatide vs Semaglutide: Complete Comparison (2026 Data)
Tirzepatide vs semaglutide with SURMOUNT-5 head-to-head data: -20.2% vs -13.7% weight loss. Full comparison of efficacy, side effects, and access.
Updated September 8, 2026
Mounjaro vs Ozempic: Which Is Better for Weight Loss and Diabetes?
Mounjaro outperformed injected Ozempic 1 mg in SURPASS-2. Compare the actual trial doses, current formulations, organ-risk indications and coverage.
Updated September 8, 2026
Peptides for Weight Loss vs GLP-1 Drugs: What the Evidence Says
Peptide chemistry does not establish efficacy. What trials show for semaglutide, tirzepatide, retatrutide and other marketed peptides.
Updated September 8, 2026
Related articles
Safety, mechanism, and context pieces that reference Tirzepatide.
GLP-1 vs GLP-2 vs GLP-3: What's the Difference?
GLP-1 and GLP-2 are real hormones. "GLP-3" is not — it's slang for retatrutide. Here's what each term actually means.
Updated September 8, 2026
Switching to Retatrutide from Tirzepatide or Semaglutide
No validated conversion or routine-care washout exists. What current trials and approval status mean for a possible switch.
Updated September 8, 2026
Dr. Jones DC on Retatrutide: Trial Results and Food Chatter Claims
Trial results, personal observations and unvalidated add-ons in Dr. Jones DC’s retatrutide video.
Updated September 8, 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.